HLA‐DRneg patients without acute promyelocytic leukemia show distinct immunophenotypic, genetic, molecular, and cytomorphologic characteristics compared to acute promyelocytic leukemia
- 16 March 2009
- journal article
- research article
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 76B (5), 321-327
- https://doi.org/10.1002/cyto.b.20475
Abstract
Background: Loss of HLA‐DR and CD34 is a well‐known characteristic of malignant promyelocytes in acute promyelocytic leukemia (APL). However, this immunophenotype is not specific for APL. The purpose of this study was to investigate whether further biological characterization of the HLA‐DRneg acute myeloid leukemia patients would allow more clearly define criteria to separate APL from non‐APL patients. Methods: Immunophenotyping, cytogenetics, molecular analyses, and cytomorphology were prospectively performed within routine leukemia diagnostics of 800 patients included in different prospective acute myeloid leukemia multicenter trials. Results: Beside 60 APL, an additional 62 HLA‐DRneg non‐APL patients were identified. The main differential characteristics of HLA‐DRneg non‐APL included high CXCR‐4 expression in most patients and almost all leukemia cells, a significantly higher proportion of patients presenting with NPM1 mutations as well as the significant association with cup‐like nuclear morphology. The biological distinctness of both leukemia subtypes was further emphasized by the complete absence of aberrant CD2 expression and increased leukocyte and platelet counts in HLA‐DRneg non‐APL patients. Even in the CD34pos subgroup of HLA‐DRneg non‐APL all those features contributed in at least the same way to the separation from APL. Conclusions: The results of the present study show that an immunophenotypic, molecular, and cytomorphologic separation of both HLA‐DRneg leukemia subgroups is possible indicating that both groups are biologically distinct. © 2009 Clinical Cytometry SocietyKeywords
This publication has 80 references indexed in Scilit:
- Endogenous Acute Phase Serum Amyloid A Lacks Pro-Inflammatory Activity, Contrasting the Two Recombinant Variants That Activate Human Neutrophils through Different ReceptorsFrontiers in Immunology, 2013
- Acute‐phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapyArthritis & Rheumatism, 2011
- Establishment of a Transgenic Mouse Model Specifically Expressing Human Serum Amyloid A in Adipose TissuePLOS ONE, 2011
- Invariant NKT cells modulate the suppressive activity of IL-10-secreting neutrophils differentiated with serum amyloid ANature Immunology, 2010
- CD36 Is a Novel Serum Amyloid A (SAA) Receptor Mediating SAA Binding and SAA-induced Signaling in Human and Rodent CellsJournal of Biological Chemistry, 2010
- The FPR2-specific ligand MMK-1 activates the neutrophil NADPH-oxidase, but triggers no unique pathway for opening of plasma membrane calcium channelsCell Calcium, 2009
- Getting to the site of inflammation: the leukocyte adhesion cascade updatedNature Reviews Immunology, 2007
- Serum Amyloid A Binding to CLA-1 (CD36 and LIMPII Analogous-1) Mediates Serum Amyloid A Protein-induced Activation of ERK1/2 and p38 Mitogen-activated Protein KinasesJournal of Biological Chemistry, 2005
- The Human Serum Amyloid A Protein (SAA) Superfamily Gene Cluster: Mapping to Chromosome 11p15.1 by Physical and Genetic Linkage AnalysisGenomics, 1994
- SAA SUPPRESSION OF IN VITRO ANTIBODY RESPONSEAnnals of the New York Academy of Sciences, 1982